Business Description
Werewolf Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US95075A1079
Total Employee Number:
14Description
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. It has one reportable segment, which focuses on the discovery and development of cancer therapeutics.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.23 | |||||
Equity-to-Asset | 0.21 | |||||
Debt-to-Equity | 3.09 | |||||
Debt-to-EBITDA | -0.76 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 14.2 | |||||
3-Year EPS without NRI Growth Rate | 10.6 | |||||
3-Year FCF Growth Rate | 5.6 | |||||
3-Year Book Growth Rate | -49.2 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 51.81 | |||||
9-Day RSI | 44.66 | |||||
14-Day RSI | 40.13 | |||||
3-1 Month Momentum % | -51.38 | |||||
6-1 Month Momentum % | -26.44 | |||||
12-1 Month Momentum % | -55.62 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.27 | |||||
Quick Ratio | 1.27 | |||||
Cash Ratio | 1.21 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -15.6 | |||||
Shareholder Yield % | -3.21 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -170.1 | |||||
ROA % | -69.15 | |||||
ROIC % | -203.7 | |||||
3-Year ROIIC % | -52.91 | |||||
ROC (Joel Greenblatt) % | -484.43 | |||||
ROCE % | -88.42 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 1.41 | |||||
Price-to-Tangible-Book | 1.41 | |||||
EV-to-EBIT | -0.16 | |||||
EV-to-EBITDA | -0.17 | |||||
EV-to-Forward-Revenue | 0.5 | |||||
EV-to-FCF | -0.16 | |||||
Price-to-GF-Value | 1.53 | |||||
| Price-to-Net-Current-Asset-Value | 5.88 | |||||
| Price-to-Net-Cash | 35.3 | |||||
Earnings Yield (Greenblatt) % | -625 | |||||
FCF Yield % | -302.77 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:HOWL
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Werewolf Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.24 | ||
| Beta | 0.3878 | ||
| 3-Year Sharpe Ratio | -0.34 | ||
| 3-Year Sortino Ratio | -0.5 | ||
| Volatility % | 99.23 | ||
| 14-Day RSI | 40.13 | ||
| 14-Day ATR ($) | 0.045138 | ||
| 20-Day SMA ($) | 0.368495 | ||
| 12-1 Month Momentum % | -55.62 | ||
| 52-Week Range ($) | 0.27 - 2.38 | ||
| Shares Outstanding (Mil) | 48.6 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Werewolf Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Werewolf Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-04 | In 125 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 43 days | ||
| General meeting for 2026 | 2026-07-03 | In 1 day | ||
| First quarter earnings results for 2026 | 2026-05-07 | 0.65 (-7.83%) | ||
| Annual report for 2025 | 2026-03-27 | 0.86 (+12.09%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-27 | 0.86 (+12.09%) | ||
| Third quarter earnings results for 2025 | 2025-11-04 | 1.31 (-1.50%) | ||
| H.C. Wainwright 27th Annual Global Investment Conference | 2025-09-08 14:00 | 1.35 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-08-14 | 1.35 (+12.50%) | ||
| General meeting for 2025 | 2025-06-12 09:00 | 1.23 (-9.56%) |
Show
Entries
Werewolf Therapeutics Inc Frequently Asked Questions
What is Werewolf Therapeutics Inc(HOWL)'s stock price today?
The current price of HOWL is $0.35. The 52 week high of HOWL is $2.38 and 52 week low is $0.27.
When is next earnings date of Werewolf Therapeutics Inc(HOWL)?
The next earnings date of Werewolf Therapeutics Inc(HOWL) is 2026-08-14 Est..
Does Werewolf Therapeutics Inc(HOWL) pay dividends? If so, how much?
Werewolf Therapeutics Inc(HOWL) does not pay dividend.
Guru Commentaries on NAS:HOWL
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Werewolf Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers